Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT05103683 Recruiting - Ovarian Cancer Clinical Trials

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

TRIO049
Start date: November 17, 2021
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

NCT ID: NCT05099978 Recruiting - Ovarian Cancer Clinical Trials

Asian Multicenter Prospective Study of ctDNA Sequencing

A-TRAIN
Start date: November 1, 2021
Phase:
Study type: Observational

This study is a genetic analysis of aberrations in circulating tumor DNA (ctDNA) in patients in Asian countries. This study protocol is divided into parts describing several subanalyses that differ in terms of cancer types, analytical methods, participating countries, and participating institutions.

NCT ID: NCT05095558 Recruiting - Clinical trials for Ovarian Cancer Recurrent

Microtransplantation for Ovarian Cancer

Start date: October 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, we will apply micro transplantation to the field of recurrent and advanced ovarian cancer to study the efficacy and safety.

NCT ID: NCT05092763 Recruiting - Ovarian Cancer Clinical Trials

Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer

FIT4SURGERY
Start date: December 10, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to test the effectiveness of a home-based, patient-tailored intervention, FIT4SURGERY, to promote physical activity among women with ovarian cancer undergoing neoadjuvant chemotherapy.

NCT ID: NCT05086692 Recruiting - Ovarian Cancer Clinical Trials

A Beta-only IL-2 ImmunoTherapY Study

ABILITY-1
Start date: August 27, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

NCT ID: NCT05082025 Active, not recruiting - Ovarian Cancer Clinical Trials

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Start date: September 27, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of copanlisib in combination with fulvestrant in advanced hormone receptor-positive (HR+) solid tumors harboring alterations that activate the Phosphatidylinositol-3 kinase (PI3K) pathway.

NCT ID: NCT05080946 Recruiting - Ovarian Cancer Clinical Trials

Using Aspirin to Improve Immunological Features of Ovarian Tumors

Start date: November 2, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma

NCT ID: NCT05080556 Recruiting - Ovarian Cancer Clinical Trials

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

ACTOv
Start date: May 24, 2023
Phase: Phase 2
Study type: Interventional

ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a proxy measure of total tumour burden and an individual patient's response to the most recent chemotherapy treatment. AT could prolong sensitivity to carboplatin and extend tumour control, while simultaneously reducing chemotherapy dose and drug-induced toxicity. Carboplatin is a low cost and low toxicity drug that has an enduring and central role in ovarian cancer treatment.

NCT ID: NCT05071937 Recruiting - Ovarian Cancer Clinical Trials

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Start date: April 13, 2023
Phase: Phase 2
Study type: Interventional

This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.

NCT ID: NCT05069818 Not yet recruiting - Ovarian Cancer Clinical Trials

Variance of HRD From Paired Ovarian Cancer

HOPEII
Start date: October 2021
Phase:
Study type: Observational

Homologous recombination deficiency (HRD) is an important biomarker of poly (ADP-ribose) polymerase inhibitor (PARPi) in patients with high-grade serous ovarian cancer (HGSOC). The stability of HRD in the recurrent HGSOC and its primary pair remains unknown.